百利天恒:BMS启动EGFR/HER3 ADC第二项全球2/3期临床

市场资讯
Aug 05

来源:医药笔记2025年8月3日,百时美施贵宝在Clinicaltrials.gov网站上注册了EGFR/HER3 ADC新药BL-B01D1(Izalontamab Brengitecan)对比铂类-培美曲塞治疗EGFR-TKI耐药的EGFR突变非小细胞肺癌的全球2/3期临床试验IZABRIGHT-Lung01。该2/3期临床计划入组596例EGFR-TKI耐药的EGFR突变非小细胞肺癌患者,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10